Drugs / KIO-301
KIO-301
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05282953 | Nov 2022 → Aug 2023 | choroideremia, retinitis pigmentosa | Kiora Pharmaceuticals, Inc. | Completed | Met primary |
News releases announcing trial results or a regulatory action · 11
| Date | Issuer | Release |
|---|---|---|
| 2026-04-14 | Kiora Pharmaceuticals, Inc. | Results Kiora's Phase 1 ABACUS Study of KIO-301 in Retinitis Pigmentosa Published in Nature Medicine; Phase 2 Trial Underway kiorapharma.com ↗ |
| 2024-11-08 | Kiora Pharmaceuticals, Inc. | Regulatory Kiora Pharmaceuticals Reports Third Quarter Results; Retinal Disease Pipeline Advancing Two Phase 2 Studies kiorapharma.com ↗
Regarding KIO-301, we recently received approval to initiate ABACUS-2, a 36-patient, multi-center, double-masked, randomized, controlled, multi-dose study in patients with ultra-low vision or no light perception due to retinitis pigmentosa. |
| 2024-10-29 | Kiora Pharmaceuticals, Inc. | Regulatory Kiora Pharmaceuticals Receives Investigational New Drug Approval to Initiate ABACUS-2, a Phase 2 Clinical Trial of KIO-301 for the Treatment of Retinitis Pigmentosa kiorapharma.com ↗ |
| 2024-07-30 | Kiora Pharmaceuticals, Inc. | Regulatory Kiora Pharmaceuticals Receives European Orphan Medicinal Product Designation for KIO-301 for the Treatment of Inherited Retinal Dystrophies kiorapharma.com ↗
Kiora Pharmaceuticals (NASDAQ: KPRX) ("Kiora" or the "Company") today announced it has received Orphan Medicinal Product Designation from the European Medicines Agency (EMA) for the treatment of a group of inherited retinal diseases (IRDs) that include retinitis pigmentosa (RP), choroideremia and more. |
| 2024-05-06 | Kiora Pharmaceuticals, Inc. | Results Kiora Pharmaceuticals Reports Additional Clinical Data for KIO-301 Showing a Statistically Significant Increase in Brain Activity in the Visual Cortex in Patients with Retinitis Pigmentosa kiorapharma.com ↗
Additional analysis of functional MRI data demonstrated a statistically significant increase in neural activity over baseline within the brain's visual processing center. |
| 2023-11-04 | Kiora Pharmaceuticals, Inc. | Results AAO Late-Breaking: Kiora's Small Molecule Photoswitch Demonstrates Meaningful Vision Improvements in Blind Patients with Retinitis Pigmentosa kiorapharma.com ↗
Kinetic visual field (Goldmann perimetry) increased significantly from baseline at days 7 and 14 post treatment (p < 0.05). |
| 2023-10-03 | Kiora Pharmaceuticals, Inc. | Regulatory Kiora Pharmaceuticals Receives Investigational New Drug Application Approval to Expand Phase 1b Study of KIO-301 in Inherited Retinal Diseases; To Enroll Patients with Choroideremia and Additional Patients with Late-Stage Retinitis Pigmentosa kiorapharma.com ↗ |
| 2023-05-01 | Kiora Pharmaceuticals, Inc. | Results Kiora Pharmaceuticals Presents Encore Imaging Results of KIO-301 for Retinitis Pigmentosa at ASNR 2023 Meeting kiorapharma.com ↗
Early results of the ABACUS phase 1b trial show KIO-301 delivered intravitreally in patients with RP may restore functional vision. |
| 2023-04-27 | Kiora Pharmaceuticals, Inc. | Results Kiora's Investigational Treatment for Retinitis Pigmentosa, KIO-301, Demonstrates Visual Function Restoration in Patients Who Are Blind kiorapharma.com ↗
Kiora Pharmaceuticals (NASDAQ: KPRX) presented preliminary results from an ongoing clinical trial showing its investigational drug, KIO-301, has the potential to restore light perception in patients who are blind or living with ultra-low vision due to retinitis pigmentosa. |
| 2022-06-27 | Kiora Pharmaceuticals, Inc. | Regulatory Kiora Pharmaceuticals Receives Clinical Trial Approval for First-in-Human Evaluation of KIO-301 to Restore Vision in Patients with Retinitis Pigmentosa kiorapharma.com ↗
Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") received approval to initiate a first-in-human clinical trial for KIO-301, which is intended to restore lost vision in patients with Retinitis Pigmentosa, a rare, inherited genetic eye disease that causes severe loss of functional vision due to degeneration of the retinal photoreceptors (rods and cones). |
| 2022-03-18 | Kiora Pharmaceuticals, Inc. | Regulatory Kiora Pharmaceuticals Granted Orphan Drug Designation for KIO-301, an Investigational Drug for the Treatment of Retinitis Pigmentosa (RP) kiorapharma.com ↗
Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), ("Kiora" or the "Company") has received Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for its investigational treatment of Retinitis Pigmentosa, KIO-301. |
All press releases naming this drug 21 releases
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | KIO-301 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05282953 ↗ |
| Known as | KIO-301, (E)- | ChEMBL registry synonym — accepted as the source's own label CHEMBL4796560 ↗ |
| Known as | KIO-301, TRANS- | ChEMBL registry synonym — accepted as the source's own label CHEMBL4796560 ↗ |
| Modality | Small molecule | “A small azobenzene photoswitch molecule (KIO-301)” PMID 41981307 ↗ Apr 2026 |
| Route | Intravitreal | “KIO-301 was administered by intravitreal injection to 12 eyes of 6 participants” PMID 41981307 ↗ Apr 2026 |